Experimental cancer combo targets Hard-to-Treat tumours

NCT ID NCT05514132

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs of tumour shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceralasertib (a targeted cancer drug) and durvalumab (an immunotherapy)
What this could lead to: If this combination proves safe and tolerable, it could lead to a new treatment option for advanced solid tumours that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) and small (14 participants) study focused on safety and dosing, not effectiveness. The combination may cause significant side effects or fail to shrink tumours.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS

Contacts and locations

Locations

Research Site

Beijing, 100021, China
Research Site

Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.